Our Company

Scientific Advisors

TALLC has built an expert team of pre-clinical and clinical scientists to guide development of TA-A001 and TALLC’s pipeline products.

Prof. Sylvain Chemtob

Dr. Chemtob is a full professor in the departments of Pediatrics, Ophthalmology and Pharmacology at Université de Montréal where he heads the Experimental Ocular Pharmacology Research Unit. Dr. Chemtob is also the Canada Research Chair in Translational Research in Vision and the Leopoldine A. Wolfe Chair in clinical/translational research to prevent blindness caused by age-related macular degeneration.

During his career Dr. Chemtob has championed the development of novel peptidomimetic drugs now entering Ph II clinical studies while his seminal work has triggered the approval of new therapies for closure of ductus arteriosus in the USA and Europe, which are now standard of care.

Prof. May Griffith

Chairman of the Scientific Advisory Committee

Dr. May Griffith is Professor at the Dept. of Ophthalmology, University of Montreal, and researcher at the Maisonneuve-Rosemont Hospital Research Centre, Montreal, Canada. Her research interests are in the area of Regenerative Medicine, with special interests in biomaterials and corneal regeneration in particular. She and her collaborators have completed two clinical studies and a pilot study where cell-free biomimetic scaffolds implanted enabled regeneration of human corneal tissue and nerves. In 2013, Dr. Griffith led her EU Nanomedicine team on the project, “I-CARE” to win the ETPN nano medicine award for regenerative medicine. 

Prof. Melanie Kelly

Department Ophthalmology & Visual Sciences, Dalhousie University

Dr. Kelly’s primary research expertise is molecular and functional pharmacology with a special interest in translational pharmacology and drug development in the cannabis/cannabinoid space. Dr. Kelly’s lab has research expertise in ocular and central nervous system pharmacology and therapeutics and examines use of drugs that target the endocannabinoid system for neurodegenerative disease and pain and inflammation.

Dr. Marie-Claude Robert

Dr Marie-Claude Robert is an Assistant Clinical Professor at the Department of Ophthalmology of the Université de Montréal, Corneal surgeon at the Centre Hospitalier de l’Université de Montréal (CHUM) and the Centre Hospitalier Universitaire Sainte-Justine and clinician-researcher at the Centre de Recherche du CHUM (CRCHUM). Dr Robert holds a Master’s degree in clinical research, is director of research for the CHUM’s Department of Ophthalmology and is principal investigator on several clinical research projects regarding corneal inflammation and transplantation. Dr. Robert is a former Harvard University Ophthalmology Alcon Scholar and recipient of the Claes Dohlman Fellowship Award for outstanding scholorship from the Massachusetts Eye and Ear Infirmary and the Retina Foundation.

Jean-François Bouchard
Prof. Jean-François Bouchard is the Executive Director of the Vision Sciences Research Group and the Director of the Neuropharmacology Laboratory at the University of Montreal School of Optometry. Prof. Bouchard’s main interests include the molecular basis of retinal development, axon guidance, synaptogenesis, and plasticity and the development of new therapeutic strategies for the treatment traumatic or inherited neuro-visual pathologies. He has published widely on the role of endocannabinoid receptors in the retina and their role in the pathogenesis of disease. Prof. Bouchard holds a Bachelor of Pharmacy Degree and Ph.D. from the University of Montreal.

Management Team

Board of Directors


Phone: 514 883 3447

Email: info@tallcinc.com


TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020